Apotex Takes Biosimilar Case To Supreme Court
Apotex Inc. is asking the U.S. Supreme Court to review the Federal Circuit's ruling that said biosimilar makers always have to provide 180-day notice of sales, calling the decision an improper...To view the full article, register now.
Already a subscriber? Click here to view full article